Objective: Bladder cancer is
most commonly observed in elderly patients. In these patients, it is not always
possible to give the necessary treatment for the disease. In this study,
definitive radiotherapy (RT) or chemoradiotherapy (CRT) results and side
effects, as well as prognostic factors, were investigated in elderly bladder
cancer patients.
Method: The results of 36
elderly patients who received definitive RT or CRT for bladder cancer between
the years 2010–2018 in Sivas Oncology Center of Cumhuriyet University Medical
Faculty were analyzed retrospectively.
Results: The median age of the patients was 75 (range, 65–84). Sixteen
patients (44%) underwent RT without chemotherapy and 20 patients (56%) received
CRT. Complete response was detected in 19 (53%) patients. The median survival
was 18 months (range 3–102 months) and the overall 2-year survival rate was
37%. Treatment response (p < .001) and performance status of the patients (p
= .001) were found to be statistically significant prognostic factors in
patients' survival. However, sex, comorbidity, Charlson Comorbidity index, risk
groups, treatment modality (RT vs. CRT), presence of in situ, grade, status of
tumor foci (unifocal vs. multifocal), degree of tumor resection in transurethral
resection of the bladder (TUR-B, complete vs. incomplete resection),
chemotherapy after CRT, concurrent chemotherapy regimen (ciplatin vs.gemcitabine),
RT dose (< 60 Gy vs. ≥60 Gy), and the device used in RT (linac vs.
TomoTherapy) were not statistically significant.
Conclusions: Good performance and completed response to
treatment in elderly bladder cancer patients positively affects survival.
Bladder cancer elderly patients radiotherapy chemoradiotherapy
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Medical Science Research Makaleler |
Yazarlar | |
Yayımlanma Tarihi | 31 Aralık 2019 |
Kabul Tarihi | 28 Kasım 2019 |
Yayımlandığı Sayı | Yıl 2019Cilt: 41 Sayı: 4 |